While broad immunosuppression can control autoimmune inflammation, it also impairs protective immune responses and increases infection risk. This trade-off has driven efforts to design treatments that act on disease-relevant pathways and cells with less disruption to broader immune defenses.
Several therapies based on this more targeted approach have already been approved. This resource examines the biology behind these treatments and the targets they act on. It also covers the tools and experiments researchers can use to investigate new candidates, including over-expression and knockout cell lines, neutralizing antibodies, and biochemical and cell-based assays.
Download this resource to
- Learn about kinase-targeted, cytokine-directed, and cell-directed therapeutic approaches
- Examine the emerging potential of immune checkpoint agonists and CAR T-cell therapy for autoimmune disease
- Explore research tools that support autoimmunity researchers in candidate screening and characterization
